Brain Cancer

After receiving a diagnosis of medulloblastoma at age 11, one woman has lived decades with the disease as her uninvited companion. Now, she writes, speaks and advocates for others facing cancer.

Here is a list of the recent trial initiations that occurred within the cancer space in October.

“Lasting Love” shares a moving and constructive message that may help support youngsters as they navigate a deep loss.

From a chemotherapy drug shortage to Eddie Van Halen revealing a cancer diagnosis, here’s what is making headlines in the cancer space this week.

After receiving a stage 4 brain cancer diagnosis, a young mother traveled from Mexico to Chicago for treatment.

Here’s a look at what’s inside our 2019 Rare Cancers special issue.

At free NCI clinics, people with some of the rarest disease get tumor analysis, counseling and expert advice.

After two years, the Biden Cancer Initiative has shuttered as former Vice President Joe Biden’s presidential campaign begins in earnest.

Long-term survivors of pediatric neuroblastoma may be at an increased risk for neurocognitive impairment – in particular, due to age at diagnosis and the type of treatment received.

The FDA has approved Zirabev, a biosimilar to Avastin, for the treatment of five types of cancer: colorectal cancer; non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

Don’t let a terminal diagnosis get you down to the point where you stop living your life. Have an adventure, buy the shoes and eat the cake.

This cancer living inside of me has been life altering. On the outside you may think that things are not so bad. What you are not seeing is that my cancer is incurable.

This essay was written by her colleagues, Jeanine Gordon and Jaclyn Andronico, Memorial Sloan Kettering Cancer Center, nominating Lisa Klempner, M.S.N., RN, OCN for CURE®’s 2019 Extraordinary Healer® Award.

From the 9/11 Victim Compensation Fund to the untimely passing of an inspirational Olympic runner, here’s what is making headlines in the cancer space this week.

Amy Setesak, B.S.N., RN, CMSRN from Memorial Sloan Kettering Cancer Center, New York, was nominated by her colleague, Aly Fox, B.S.N., RN, CMSRN, for CURE®’s Extraordinary Healer® Award.

Four out of 100. That is the survival rate for stage 4 glioblastoma: four percent.

Learn about awareness and actions strategies during Brain Tumor Awareness Month and beyond.

From the first annual Glioblastoma Awareness Day to politics and today’s top performers, here’s what’s making headlines in the cancer space this week.​

Carrying chronic illness can be very difficult, but there are ways to navigate the world without being crushed by the weight of what we cannot control.

Children diagnosed with embryonal brain tumors who have experienced treatment-related hearing loss exhibited greater difficulties reading – in particular, with phonological skills and processing speed, according to study results.

From National Women's Health Week to today’s top athletes, here’s what’s making headlines in the cancer space this week.

The phase 3 CheckMate 498 trial, designed to compare Opdivo with Temodal for the treatment of patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme failed to meet its primary endpoint of increasing overall survival.

From a sweet fundraiser for breast cancer to today’s top performers and athletes, here’s what’s making headlines in the cancer space this week.

Evaluations can identify the potential for drug interactions and predict whether older patients are fit for chemotherapy.

Researchers examine genomic mutations with tumor response to Keytruda and Opdivo in patients with GBM, highlighting the potential for a molecular, personalized approach to treat certain patients.

Patients with glioblastoma may lack easy access to clinical trials and off-label treatments, despite showing an interest in learning more about them.

Administration of Opdivo (nivolumab) before surgical resection in patients with glioblastoma appeared safe and feasible, according to phase 2 trial results published in Nature Medicine.

The Food and Drug Administration (FDA) Expanded Access program appeared to have broad use, involved a wide variety of patients and drugs, and derived clinical benefit, according to an initial summary published in JAMA Oncology.

A preclinical study showed that FGL2 protein suppression may stop tumor cell growth in patients with glioblastoma.